UNASSIGNED: 8568 Background: We have seen spectacular improvement in the survival rates of pediatric @entity1 suffering from @entity5 , but long term effects of the @entity5 as well as the treatment modalities uised remain a cause for concern especially in countries with limited resources. We have evaluated over a ten year period the long term effects of @entity8253 in pediatric @entity1 Methods: Non-invasive cardiological methods were used to detect these fatal side effects early. We evaluated 58 @entity1 in the age group of 1   - 13 years admitted with various @entity5 in the period 1992 -1997. They were treated for @entity981 (30), @entity978 (12), Neurblastoma(6). The doses ranged from 180 mg/mt(2) to 350mg/mt(2) of @entity632 . Their Echocardiograms and ECG was done at baseline before administration of Chemotherapy and then repeated 1year after the last injection of @entity8253 .and for long term follow up they were evaluated again at 3 years The @entity1002 ( @entity1002 ) was calculated. @entity1370 was defined as decrease in left ventricular ejection fraction of more than 10% to a final left ventricular ejection fraction < or = 50%. RESULTS: There were 32 males and 26 females. The @entity1002 decreased more than 10% to a level< or + 50% in 7 @entity1 (12.06%). The @entity1002 decreased from 56    1.8 to 53.86    1.32 (> 0.01) in patent with no @entity1370 . For those who had a fall in @entity1002 the values were 58.36    1.73 to 43.26    2.1 (p <0.001). Out of the seven @entity1 showing a significant fall in @entity1002 there was only one who had a @entity5948 dose of less than 200mg/mt(2). On evaluation at 3 years 52 responded. There were now 9(7+2) @entity1 who had satisfied the criteria of @entity1370 . Their @entity1002 were 59.26+1.58 to 47.89+1.46 to 46.35 +2.3 (p,.001). On using a cut off at 1 year of 5% fall in @entity1002 the sensitivity increased to 89% and the specificity of 69% for latter @entity1370 . CONCLUSIONS: Thus there is a need to revise the @entity137 criteria and have a high index of suspicion. These @entity1 need a long term follow up for improving their Quality of Life. No significant financial relationships to disclose.

Late effects: Ten years long term follow up of pediatric oncology XXXX - From nihilism to cautious optimism.

@entity1 :: ('9606', 'Species') :: ['children', 'patients'] @entity632 :: ('MESH:D004317', 'Chemical') :: ['Doxorubicin'] @entity981 :: ('MESH:D054198', 'Disease') :: ['ALL'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity8253 :: ('MESH:D018943', 'Chemical') :: ['Anthracyclines'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'malignancies', 'tumors'] @entity5948 :: ('D018943', 'Chemical') :: ['anthracycline'] @entity978 :: ('MESH:D006689', 'Disease') :: ['Wilms (10) Hodgkins Lymphoma'] @entity1370 :: ('MESH:D066126', 'Disease') :: ['Cardiotoxicity', 'cardiotoxicity'] @entity1002 :: ('MESH:D018487', 'Disease') :: ['LVEF', 'Left Ventricular Ejection Fraction']
@entity1 :: (9606,Species) :: ['patients']
